219 related articles for article (PubMed ID: 23517793)
21. Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment.
Lukashevich V; Schweizer A; Foley JE; Dickinson S; Groop PH; Kothny W
Vasc Health Risk Manag; 2013; 9():21-8. PubMed ID: 23378769
[TBL] [Abstract][Full Text] [Related]
22. The efficacy and safety of adding either vildagliptin or glimepiride to ongoing metformin therapy in patients with type 2 diabetes mellitus.
Kim G; Oh S; Jin SM; Hur KY; Kim JH; Lee MK
Expert Opin Pharmacother; 2017 Aug; 18(12):1179-1186. PubMed ID: 28714741
[TBL] [Abstract][Full Text] [Related]
23. Glycemic effects of vildagliptin and metformin combination therapy in Indian patients with type 2 diabetes: an observational study.
Chatterjee S; Chatterjee S
J Diabetes; 2014 May; 6(3):237-42. PubMed ID: 23879210
[TBL] [Abstract][Full Text] [Related]
24. Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients.
Derosa G; Bonaventura A; Bianchi L; Romano D; Fogari E; D'Angelo A; Maffioli P
Metabolism; 2014 Jul; 63(7):957-67. PubMed ID: 24874591
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and tolerability of vildagliptin as an add-on to glimepiride in Japanese patients with Type 2 diabetes mellitus.
Kikuchi M; Haneda M; Koya D; Tobe K; Onishi Y; Couturier A; Mimori N; Inaba Y; Goodman M
Diabetes Res Clin Pract; 2010 Sep; 89(3):216-23. PubMed ID: 20537746
[TBL] [Abstract][Full Text] [Related]
26. Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential.
Mikhail N
Vasc Health Risk Manag; 2008; 4(6):1221-7. PubMed ID: 19337535
[TBL] [Abstract][Full Text] [Related]
27. The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis.
Ito M; Abe M; Okada K; Sasaki H; Maruyama N; Tsuchida M; Higuchi T; Kikuchi F; Soma M
Endocr J; 2011; 58(11):979-87. PubMed ID: 21921362
[TBL] [Abstract][Full Text] [Related]
28. Comparison of vildagliptin and glimepiride: effects on glycaemic control, fat tolerance and inflammatory markers in people with type 2 diabetes.
Derosa G; Bonaventura A; Bianchi L; Romano D; Fogari E; D'Angelo A; Maffioli P
Diabet Med; 2014 Dec; 31(12):1515-23. PubMed ID: 24824633
[TBL] [Abstract][Full Text] [Related]
29. Factors associated with the glucose-lowering effect of vildagliptin identified from the results of the oral glucose tolerance test in Japanese patients with type 2 diabetes.
Nakamura A; Terauchi Y
Endocr J; 2013; 60(1):45-9. PubMed ID: 22972222
[TBL] [Abstract][Full Text] [Related]
30. Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.
Mikhail N
Expert Opin Investig Drugs; 2008 Jun; 17(6):845-53. PubMed ID: 18491986
[TBL] [Abstract][Full Text] [Related]
31. Real-life efficacy and safety of vildagliptin compared with sulfonylureas as add-on to metformin in patients with type 2 diabetes mellitus in Germany.
Göke R; Gruenberger JB; Bader G; Dworak M
Curr Med Res Opin; 2014 May; 30(5):785-9. PubMed ID: 24328429
[TBL] [Abstract][Full Text] [Related]
32. DPP-4 inhibitor treatment: β-cell response but not HbA
Kozlovski P; Bhosekar V; Foley JE
Vasc Health Risk Manag; 2017; 13():123-126. PubMed ID: 28408838
[TBL] [Abstract][Full Text] [Related]
33. A double-blind, randomized trial, including frequent patient-physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study.
Hassanein M; Abdallah K; Schweizer A
Vasc Health Risk Manag; 2014; 10():319-26. PubMed ID: 24920915
[TBL] [Abstract][Full Text] [Related]
34. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study.
Garber AJ; Schweizer A; Baron MA; Rochotte E; Dejager S
Diabetes Obes Metab; 2007 Mar; 9(2):166-74. PubMed ID: 17300592
[TBL] [Abstract][Full Text] [Related]
35. Glucagon dynamics during hypoglycaemia and food-re-challenge following treatment with vildagliptin in insulin-treated patients with type 2 diabetes.
Farngren J; Persson M; Schweizer A; Foley JE; Ahrén B
Diabetes Obes Metab; 2014 Sep; 16(9):812-8. PubMed ID: 24612221
[TBL] [Abstract][Full Text] [Related]
36. Translating science into clinical practice: focus on vildagliptin in combination with metformin.
Barnett AH
Diabetes Obes Metab; 2009 May; 11 Suppl 2():18-26. PubMed ID: 19385980
[TBL] [Abstract][Full Text] [Related]
37. Treatment adherence with vildagliptin compared to sulphonylurea as add-on to metformin in Muslim patients with type 2 diabetes mellitus fasting during Ramadan.
Hanif W; Malik W; Hassanein M; Kamal A; Geransar P; Andrews C; Azam M; Barnett AH
Curr Med Res Opin; 2013 Jul; 29(7):807-11. PubMed ID: 23659561
[TBL] [Abstract][Full Text] [Related]
38. [A combination of dipeptidyl peptidase-4 inhibitor and metformin in the treatment of patients with type 2 diabetes mellitus: effective control of glycemia, weight, and quantitative body composition].
Shestakova MV; Suhareva OIu; Chernova TO; Shmushkovich IA; Aleksandrov AA; Il'in AV; Dedov II
Ter Arkh; 2013; 85(8):49-55. PubMed ID: 24137964
[TBL] [Abstract][Full Text] [Related]
39. A randomized controlled trial to compare the effects of sulphonylurea gliclazide MR (modified release) and the DPP-4 inhibitor vildagliptin on glycemic variability and control measured by continuous glucose monitoring (CGM) in Brazilian women with type 2 diabetes.
Vianna AGD; Lacerda CS; Pechmann LM; Polesel MG; Marino EC; Faria-Neto JR
Diabetes Res Clin Pract; 2018 May; 139():357-365. PubMed ID: 29596951
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety comparison of add-on therapy with liraglutide, saxagliptin and vildagliptin, all in combination with current conventional oral hypoglycemic agents therapy in poorly controlled Chinese type 2 diabetes.
Li CJ; Yu Q; Yu P; Zhang QM; Ding M; Liu XJ; Yu DM
Exp Clin Endocrinol Diabetes; 2014 Sep; 122(8):469-76. PubMed ID: 24838155
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]